DR not main cause of blindness in diabetics

Article

Diabetic retinopathy (DR) is not the leading cause of ocular co-morbidity in diabetic subjects, according to a study published in the June 2008 issue of the British Journal of Ophthalmology.

Diabetic retinopathy (DR) is not the leading cause of ocular co-morbidity in diabetic subjects, according to a study published in the June 2008 issue of the British Journal of Ophthalmology.

Peter H. Scanlon, MBBS, MD, FRCP, DCH, DRCOG, DO, MRCOphth of Cheltenham General Hospital and colleagues conducted slip-lamp biomicroscopy examinations on diabetic subjects (n=1549) following assessment of best corrected visual acuity (BCVA) by a standardized logarithm of minimum angle resolution (logMAR).

The researchers found subnormal vision (logMAR ≥0.3) in 9.0% of subjects; blindness (logMAR ≥1.3), in 0.45%. For any given eye, sensitivity of subnormal vision was 33.4%, specificity was 85.9%, positive status was 18.6% and negative status was 93.0% predictive of DR. Lenticular opacity, macular degeneration, diabetic maculopathy, other media causes including corneal opacity, and amblyopia were found to be contributory causes of moderate visual loss (logMAR 0.50–0.98) or acuity blindness (logMAR ≥1.0) in 49%, 29%, 15%, 13% and 10% of subjects, respectively.

The researchers concluded that BCVA in isolation is not a reliable indicator of DR, and that DR is not the primary cause of vision loss in diabetic subjects.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.